Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Novelion Therapeutics Inc | 24 |
| 2 | Pfizer Inc | 23 |
| 3 | Bausch Health Companies Inc | 19 |
| 4 | BASF SE | 9 |
| 5 | Government of the United States of America | 8 |
| 6 | Baxter International Inc | 7 |
| 7 | Novartis AG | 7 |
| 8 | DSM Firmenich AG | 6 |
| 9 | Mass General Brigham Inc | 6 |
| 10 | Les Laboratoires Servier SAS | 5 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 123 |
| 2 | A61P | Therapeutic activity (drug indications) | 119 |
| 3 | C07D | Heterocyclic compounds | 95 |
| 4 | A61N | 26 | |
| 5 | C07K | Peptides | 25 |
| 6 | A61F | 12 | |
| 7 | A61Q | Cosmetics, personal care | 12 |
| 8 | A23V | Foods, foodstuffs - indexing scheme | 10 |
| 9 | C07F | Organometallic compounds | 10 |
| 10 | A23L | Foods and beverages (general) | 9 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method for extraction and separation of visnagin | 2012 | 1 | |
| Method for extraction and separation of visnagin | 2015 | 0 | |
| CHEMICAL STRUCTURE TRANSFORMATION OF VISNAGIN FOR PREVENTION OR TREATMENT OF DISEASES IN CENTRAL NERVOUS SYSTEM | 2011 | 0 | |
| Method for the preparation of visnagin from chellol and new compositions of matter | 1953 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Lucia Bovalini | University of Siena | 5 |
| 2 | Veronika Butterweck | University of Florida | 5 |
| 3 | P. Martelli | University of Siena | 4 |
| 4 | Saeed R. Khan | University of Florida | 3 |
| 5 | Larry A. Sklar | University of New Mexico | 3 |
| 6 | Neslihan Beyazıt | Mustafa Kemal University | 3 |
| 7 | Keriman Günaydın | Mustafa Kemal University | 3 |
| 8 | Pattaraporn Vanachayangkul | University of Florida | 3 |
| 9 | Matthew Saunders | University of New Mexico | 3 |
| 10 | Steven W. Graves | Los Alamos National Laboratory | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase | 2014 | 138 | Mitochondrial Function and Pathology |
| A new steroid glycoside and furochromones from Cyperus rotundus L. | 2007 | 84 | Botany and Plant Ecology Studies |
| Prevention of renal crystal deposition by an extract of Ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats | 2010 | 82 | Kidney Stones and Urolithiasis Treatments |
| Synthesis of New Visnagen and Khellin Furochromone Pyrimidine Derivatives and Their Anti-Inflammatory and Analgesic Activity | 2011 | 81 | Synthesis and biological activity |
| Visnagin attenuates acute pancreatitis via Nrf2/NFκB pathway and abrogates associated multiple organ dysfunction | 2019 | 76 | Pancreatitis Pathology and Treatment |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of visnagin?
Which organizations hold the most patents for visnagin?
What are the most cited published research papers on visnagin?
What research areas are most prominent in visnagin publications?
How is visnagin patent activity distributed across technical classifications?